< Back to latest news & events

Articles

G2/24: A new referral to the Enlarged Board seeks to clarify whether a third party who intervened during appeal proceedings can acquire full appellant status

December 2024

In the referring decision, T1286/23, the Board of Appeal referred the following questions to the Enlarged Board of Appeal:

After the withdrawal of all appeals, may the proceedings be continued with a third party who intervened during the appeal proceedings? In particular, may the third party acquire an appellant status corresponding to the status of a person entitled to appeal as a party adversely affected by the decision under appeal?

Background

A third party may intervene[1] in opposition proceedings after the opposition period has expired if proceedings for infringement have been instituted against them, or following a request of the patentee to cease alleged infringement, the third party has instituted proceedings for a declaration of non-infringement. An admissible intervention is treated as an opposition. Accordingly, an intervener’s opposition is not constrained by what has already been filed by the other opponents; the intervener is entitled to rely on fresh grounds, facts, evidence, and arguments despite their opposition being filed outside the 9-month opposition period.

The Referral

The present case concerned Foreo’s patent for an oscillating handheld skin cleanser. An opposition was filed by Beurer and, while the opposition was pending, the patentee threatened a third party, Geske, for patent infringement. Geske tried to intervene, but, as threats for infringement did not constitute proceedings for infringement, the intervention failed.

Geske tried again after filing a request for non-infringement at the Dusseldorf District Court. However, although the suit had been initiated, the Opposition Division noted that, under German law, a declaration for non-infringement only became “pending” upon receipt of the action by the defendant. By the time receipt of the action was acknowledged by Foreo some months later, the opposition had concluded with the maintenance of the patent in amended form.  However, fortunately for Geske, the opponent (Beurer) appealed, allowing Geske to file an admissible intervention during the appeal.

Beurer, however, withdrew its appeal after issuance of the summons. This drew the validity of Geske’s intervention into question, as the Enlarged Board in G3/04 had already decided that, after withdrawal of the sole appeal, proceedings could not be continued by the intervener. The patentee argued that there were no circumstances to suggest that G3/04 was no longer good law.  However, the referring Board disagreed noting that, unlike in common law systems, Enlarged Board of Appeal decisions were only binding on the Board of the referring decision. The referring Board considered a fresh referral to be necessary because the Enlarged Board in G3/04 had taken a purely literal interpretation of the law, without looking at its legislative intent. This was inconsistent with e.g., the travaux préparatoires, which did not appear to limit the status of an intervener to one of a non-appealing opponent but to give the intervener full opponent status. It would be contradictory for a party with full opponent status to lose that status at appeal.

Conclusion

This case is interesting because it seeks to reopen a question already considered by an Enlarged Board. The referring Board also took the opportunity to consider whether the advent of the UPC justified changing the standing of interveners, given that an alternative forum for central revocation was now available. In answering its own question, the referring Board highlighted the advantages in terms of cost and simplicity of EPO appeal procedures compared to court procedures, such as the UPC. In the Board’s view, it could not have been the legislative intent to deprive interveners from the EPO route, since the travaux préparatoires envisaged permitting a party threatened with an infringement action to conduct validity proceedings before the EPO, even where a common court, comparable to the UPC, would also have been available for such actions.

[1] Article 105 EPC


This article was prepared by Partner & Patent Attorney Hsu Min Chung.

Latest updates

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Read article

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Read article

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Read article

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

Often Copied, Never Equaled: When Do Everyday Items Become Subject of Copyright?

The  borderline between ‘pure’ works of art and mere utilitarian objects” –  Can iconic, yet everyday products be protected under copyright? The above question was posed by Advocate General in …

Read article

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Read article

The end of the Brexit overhang for trade marks: review, refile and revoke.

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade …

Read article
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details